

## PEI Pharmacare Bulletin

Issue (2020 - 6)

December 14, 2020

### NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY (EFFECTIVE DATE: December 28, 2020)

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN/PDIN	MFR
Dolutegravir sodium/lamivudine	Dovato	50 mg/300 mg	Tablet	02491753	VII
Criteria	Open benefit				
Program Eligibility	HIV Drug Program				
Latanoprostene bunod	Vyzulta	0.024 %	Ophthalmic Drops	02484218	BLO
Criteria	Open benefit				
Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Program, Seniors Drug Program, Nursing Home Program, Catastrophic Drug Program				
Polyethylene Glycol 3350	PEG 3350 (various)	17 g/dose	Powder	09991054*	Various
Criteria	Open benefit				
	*Note: please use pseudo-DIN 09991054 for billing purposes.				
Program Eligibility	Financial Assistance Program, Nursing Home Drug Program				

### BENEFIT STATUS/CRITERIA CHANGES (EFFECTIVE DATE: December 28, 2020)

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN/PDIN	MFR
Lactulose	Lactulose (various)	667 mg/ml	Syrup	Various	Various
Criteria	This product will move from open benefit status, to restricted status, with the following criteria: For the treatment of hepatic encephalopathy				
	<b>Clients currently accessing this medication for indications other than hepatic encephalopathy will have until April 1, 2021 to transition to an alternative medication.</b>				
Program Eligibility	Financial Assistance Program, Nursing Home Drug Program				